Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Relationships between Lower Limb Muscle Strength Impairments and Physical Limitations in DM1.

Petitclerc É, Hébert LJ, Mathieu J, Desrosiers J, Gagnon C.

J Neuromuscul Dis. 2018;5(2):215-224. doi: 10.3233/JND-170291.

PMID:
29865087
2.

A 9-year follow-up study of quantitative muscle strength changes in myotonic dystrophy type 1.

Gagnon C, Petitclerc É, Kierkegaard M, Mathieu J, Duchesne É, Hébert LJ.

J Neurol. 2018 Jul;265(7):1698-1705. doi: 10.1007/s00415-018-8898-4. Epub 2018 May 21.

PMID:
29785524
3.

Responsiveness of performance-based outcome measures for mobility, balance, muscle strength and manual dexterity in adults with myotonic dystrophy type 1.

Kierkegaard M, Petitclerc É, Hébert LJ, Mathieu J, Gagnon C.

J Rehabil Med. 2018 Feb 28;50(3):269-277. doi: 10.2340/16501977-2304.

4.

Is one trial enough for repeated testing? Same-day assessments of walking, mobility and fine hand use in people with myotonic dystrophy type 1.

Kierkegaard M, Petitclerc E, Hébert LJ, Gagnon C.

Neuromuscul Disord. 2017 Feb;27(2):153-158. doi: 10.1016/j.nmd.2016.11.018. Epub 2016 Dec 5.

PMID:
28062219
5.

Lower limb muscle strength impairment in late-onset and adult myotonic dystrophy type 1 phenotypes.

Petitclerc É, Hébert LJ, Mathieu J, Desrosiers J, Gagnon C.

Muscle Nerve. 2017 Jul;56(1):57-63. doi: 10.1002/mus.25451. Epub 2016 Nov 25.

PMID:
27784130
6.

Lower limb muscle impairment in myotonic dystrophy type 1: the need for better guidelines.

Petitclerc É, Hébert LJ, Desrosiers J, Gagnon C.

Muscle Nerve. 2015 Apr;51(4):473-8. doi: 10.1002/mus.24521. Epub 2015 Feb 25. Review.

PMID:
25399769
7.

Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships.

Fortin S, Wei L, Moreau E, Lacroix J, Côté MF, Petitclerc E, Kotra LP, Gaudreault RC.

Eur J Med Chem. 2011 Nov;46(11):5327-42. doi: 10.1016/j.ejmech.2011.08.034. Epub 2011 Aug 30.

PMID:
21920638
8.

Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI.

Faucher L, Guay-Bégin AA, Lagueux J, Côté MF, Petitclerc E, Fortin MA.

Contrast Media Mol Imaging. 2011 Jul-Aug;6(4):209-18. doi: 10.1002/cmmi.420. Epub 2010 Dec 1.

PMID:
21861281
9.

Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4.

Fortin S, Wei L, Moreau E, Lacroix J, Côté MF, Petitclerc E, Kotra LP, C-Gaudreault R.

J Med Chem. 2011 Jul 14;54(13):4559-80. doi: 10.1021/jm200488a. Epub 2011 Jun 13.

10.

Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation.

Patenaude A, Fortin JS, Deschenes R, Côté MF, Lacroix J, C-Gaudreault R, Petitclerc E.

Can J Physiol Pharmacol. 2010 Nov;88(11):1102-14. doi: 10.1139/y10-084.

PMID:
21076498
11.

Vascular smooth muscle contractility assays for inflammatory and immunological mediators.

Marceau F, deBlois D, Petitclerc E, Levesque L, Drapeau G, Audet R, Godin D, Larrivée JF, Houle S, Sabourin T, Fortin JP, Morissette G, Gera L, Bawolak MT, Koumbadinga GA, Bouthillier J.

Int Immunopharmacol. 2010 Nov;10(11):1344-53. doi: 10.1016/j.intimp.2010.08.016. Epub 2010 Sep 8. Review.

12.

ASK1-P38 pathway is important for anoikis induced by microtubule-targeting aryl chloroethylureas.

Fortin J, Patenaude A, Deschesnes RG, Côté MF, Petitclerc E, C-Gaudreault R.

J Pharm Pharm Sci. 2010;13(2):175-90.

13.

Synthesis, antiproliferative activity evaluation and structure-activity relationships of novel aromatic urea and amide analogues of N-phenyl-N'-(2-chloroethyl)ureas.

Fortin S, Moreau E, Lacroix J, Côté MF, Petitclerc E, C-Gaudreault R.

Eur J Med Chem. 2010 Jul;45(7):2928-37. doi: 10.1016/j.ejmech.2010.03.018. Epub 2010 Mar 25.

PMID:
20400211
14.

Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site.

Fortin S, Lacroix J, Côté MF, Moreau E, Petitclerc E, C-Gaudreault R.

Biol Proced Online. 2010 Apr 8;12(1):113-7. doi: 10.1007/s12575-010-9029-5.

15.

Tumor cells expressing tissue factor influence the migration of smooth muscle cells in a catalytic activity-dependent way.

Brousseau C, Morissette G, Fortin JP, Marceau F, Petitclerc E.

Can J Physiol Pharmacol. 2009 Sep;87(9):694-701. doi: 10.1139/y09-063.

PMID:
19794520
16.

Mechanism of action of N-phenyl-N'-(2-chloroethyl)ureas in the colchicine-binding site at the interface between alpha- and beta-tubulin.

Fortin S, Wei L, Moreau E, Labrie P, Petitclerc E, Kotra LP, C-Gaudreault R.

Bioorg Med Chem. 2009 May 15;17(10):3690-7. doi: 10.1016/j.bmc.2009.03.056. Epub 2009 Apr 1.

PMID:
19398206
17.

Receptor tyrosine kinases as mediators of injury-induced bradykinin B1 receptor expression in rabbit aortic smooth muscle.

Koumbadinga GA, Petitclerc E, Bouthillier J, Adam A, Marceau F.

Eur J Pharmacol. 2009 Mar 15;606(1-3):233-9. doi: 10.1016/j.ejphar.2008.12.058. Epub 2009 Jan 21.

PMID:
19374866
18.

On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study.

Vallières K, Petitclerc E, Laroche G.

Vascul Pharmacol. 2009 Jul;51(1):50-6. doi: 10.1016/j.vph.2009.02.003. Epub 2009 Mar 1.

PMID:
19258052
19.

Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.

Fortin JS, Côté MF, Lacroix J, Desjardins M, Petitclerc E, C-Gaudreault R.

Bioorg Med Chem. 2008 Aug 1;16(15):7277-90. doi: 10.1016/j.bmc.2008.06.028. Epub 2008 Jun 20.

PMID:
18617414
20.

Aromatic 2-chloroethyl urea derivatives and bioisosteres. Part 2: Cytocidal activity and effects on the nuclear translocation of thioredoxin-1, and the cell cycle progression.

Fortin JS, Côté MF, Lacroix J, Petitclerc E, C-Gaudreault R.

Bioorg Med Chem. 2008 Aug 1;16(15):7477-88. doi: 10.1016/j.bmc.2008.06.006. Epub 2008 Jun 10.

PMID:
18579387
21.

Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.

Fortin JS, Côté MF, Lacroix J, Patenaude A, Petitclerc E, C-Gaudreault R.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3526-31. doi: 10.1016/j.bmcl.2008.05.028. Epub 2008 May 10.

PMID:
18502639
22.

Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site.

Fortin JS, Lacroix J, Desjardins M, Patenaude A, Petitclerc E, C-Gaudreault R.

Bioorg Med Chem. 2007 Jul 1;15(13):4456-69. Epub 2007 Apr 22.

PMID:
17498960
23.
24.

New soft alkylating agents with enhanced cytotoxicity against cancer cells resistant to chemotherapeutics and hypoxia.

Patenaude A, Deschesnes RG, Rousseau JL, Petitclerc E, Lacroix J, Côté MF, C-Gaudreault R.

Cancer Res. 2007 Mar 1;67(5):2306-16.

25.

Microtubule-destabilizing agents induce focal adhesion structure disorganization and anoikis in cancer cells.

Deschesnes RG, Patenaude A, Rousseau JL, Fortin JS, Ricard C, Côté MF, Huot J, C-Gaudreault R, Petitclerc E.

J Pharmacol Exp Ther. 2007 Feb;320(2):853-64. Epub 2006 Nov 10.

26.

MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment.

Bérubé M, Deschambeault A, Boucher M, Germain L, Petitclerc E, Guérin SL.

Mol Vis. 2005 Dec 14;11:1101-11.

27.

Optimized N-phenyl-N'-(2-chloroethyl)ureas as potential antineoplastic agents: synthesis and growth inhibition activity.

Moreau E, Fortin S, Desjardins M, Rousseau JL, Petitclerc E, C-Gaudreault R.

Bioorg Med Chem. 2005 Dec 15;13(24):6703-12. Epub 2005 Sep 13.

PMID:
16165366
28.

Improving arterial prosthesis neo-endothelialization: application of a proactive VEGF construct onto PTFE surfaces.

Crombez M, Chevallier P, -Gaudreault RC, Petitclerc E, Mantovani D, Laroche G.

Biomaterials. 2005 Dec;26(35):7402-9.

PMID:
16005960
29.

Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin.

Bérubé M, Talbot M, Collin C, Paquet-Bouchard C, Germain L, Guérin SL, Petitclerc E.

Int J Oncol. 2005 Feb;26(2):405-13.

PMID:
15645125
30.
31.

Engineering surfaces for bioconjugation: developing strategies and quantifying the extent of the reactions.

Gauvreau V, Chevallier P, Vallières K, Petitclerc E, Gaudreault RC, Laroche G.

Bioconjug Chem. 2004 Sep-Oct;15(5):1146-56.

PMID:
15366971
32.

Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.

Petitclerc E, Deschesnes RG, Côté MF, Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J, Mounetou E, Madelmont JC, C -Gaudreault R.

Cancer Res. 2004 Jul 1;64(13):4654-63.

33.

Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.

Stefansson S, McMahon GA, Petitclerc E, Lawrence DA.

Curr Pharm Des. 2003;9(19):1545-64. Review.

PMID:
12871067
34.

Kinin receptors: functional aspects.

Marceau F, Sabourin T, Houle S, Fortin JP, Petitclerc E, Molinaro G, Adam A.

Int Immunopharmacol. 2002 Dec;2(13-14):1729-39. Review.

PMID:
12489786
35.

Effect of reproductive hormones on ovarian epithelial tumors: II. Effect on angiogenic activity.

Chen C, Petitclerc E, Zhou H, Brooks PC, Sun T, Yu MC, Zheng W, Dubeau L.

Cancer Biol Ther. 2002 May-Jun;1(3):307-12.

PMID:
12432284
36.

Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo.

Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE, Brooks PC.

J Cell Biol. 2001 Sep 3;154(5):1069-79. Erratum in: J Cell Biol 2001 Nov 26;155(5):859. Yuen SM [corrected to Moon YS].

37.

Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.

McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA.

J Biol Chem. 2001 Sep 7;276(36):33964-8. Epub 2001 Jul 5.

38.

The chick embryo metastasis model.

Petitclerc E, Brooks PC.

Methods Mol Med. 2001;58:173-87. doi: 10.1385/1-59259-137-X:173.

PMID:
21340857
39.

Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1.

Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA.

J Biol Chem. 2001 Mar 16;276(11):8135-41. Epub 2000 Nov 16.

40.

The chimeric human/mouse model of angiogenesis.

Petitclerc E, von Schalscha T, Brooks PC.

Methods Mol Biol. 2000;137:213-21. No abstract available.

PMID:
10948540
41.

New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo.

Petitclerc E, Boutaud A, Prestayko A, Xu J, Sado Y, Ninomiya Y, Sarras MP Jr, Hudson BG, Brooks PC.

J Biol Chem. 2000 Mar 17;275(11):8051-61.

42.

Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival.

Petitclerc E, Strömblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA, Brooks PC.

Cancer Res. 1999 Jun 1;59(11):2724-30.

43.

Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells.

Potvin F, Petitclerc E, Marceau F, Poubelle PE.

J Immunol. 1997 Feb 15;158(4):1872-9.

PMID:
9029128
44.

Pathologic leukocyte infiltration of the rabbit aorta confers a vasomotor effect to chemotactic peptides through cyclooxygenase-derived metabolites.

Petitclerc E, Levesque L, Grose JH, Poubelle PE, Marceau F.

J Immunol. 1996 May 1;156(9):3426-34.

PMID:
8617969
45.

Further analysis of the upregulation of bradykinin B1 receptors in isolated rabbit aorta by using metabolic inhibitors.

Audet R, Petitclerc E, Drapeau G, Rioux F, Marceau F.

Eur J Pharmacol. 1994 Dec 27;271(2-3):551-5.

PMID:
7705458
46.

Recombinant human hemoglobin inhibits both constitutive and cytokine-induced nitric oxide-mediated relaxation of rabbit isolated aortic rings.

Rioux F, Petitclerc E, Audet R, Drapeau G, Fielding RM, Marceau F.

J Cardiovasc Pharmacol. 1994 Aug;24(2):229-37.

PMID:
7526054
47.

Epidermal growth factor-induced rapid relaxation of the isolated rabbit mesenteric artery.

Petitclerc E, Poubelle PE, Marceau F.

Eur J Pharmacol. 1994 Jun 23;259(1):91-4.

PMID:
7957600
48.
49.

Dissociation of the antimicrobial activity of bacitracin USP from its renovascular effects.

Drapeau G, Petitclerc E, Toulouse A, Marceau F.

Antimicrob Agents Chemother. 1992 May;36(5):955-61.

50.

Effects of interleukin-1 receptor antagonist on three types of responses to interleukin-1 in rabbit isolated blood vessels.

Petitclerc E, Abel S, deBlois D, Poubelle PE, Marceau F.

J Cardiovasc Pharmacol. 1992 May;19(5):821-9.

PMID:
1381781

Supplemental Content

Loading ...
Support Center